Substance-Related and Addiction Disorders

Impact of Substance-Related & Addiction Disorders on Overall Health

  • Affect every body system; potential for acute emergencies (e.g., overdose, withdrawal seizures) and chronic disease (e.g., cirrhosis\text{cirrhosis}, cardiomyopathy).

  • Diminish mental-health stability; often precipitate or worsen mood, anxiety, psychotic, and trauma-related disorders.

  • Ripple effects on family / social systems: lost productivity, financial strain, interpersonal conflict, child neglect, intimate-partner violence.

  • Heightened risk for legal problems (e.g., DUI\text{DUI}, possession charges) and societal costs (health-care expenditures, criminal-justice involvement).

Epidemiology & Etiology

  • Substance use can begin at any age; adolescents carry the highest incidence due to neurodevelopmental vulnerability and peer influence.

  • Motivations include self-medication for untreated depression/anxiety, pain, and stress.

  • Etiology is multifactorial: biologic, psychologic, social, cultural, and spiritual dimensions interact.

Neurobiology: The Reward Pathway

  • Limbic system releases a sudden dopamine burst → perception of reward.

  • Basal ganglia
    • Governs motivation, habit formation.
    • Excessive stimulation → euphoria, reinforcing continued use.

  • Amygdala
    • Registers threat → anxiety, irritability, powerful cravings in abstinence.

  • Prefrontal cortex
    • Executive function; chronic use blunts judgment → compulsive drug-seeking despite negative consequences.

Risk & Protective Factors

  • Risk: un/undertreated mental illness, chronic stress, genetic predisposition, peer pressure, physical/sexual abuse, poverty.

  • Protective: strong family bonds, consistent caregiver involvement, prosocial peers, gainful employment, accessible community resources.

Common Comorbidities

  • Cardiovascular: heart disease, stroke\text{heart disease, stroke}

  • Hepatic: hepatitis, cirrhosis\text{hepatitis, cirrhosis}

  • Dental decay (esp. methamphetamine, opioids)

  • Co-occurring psychiatric illness (dual diagnosis)

Clinical Presentation by Substance Class

Alcohol

  • Use: mood & behavior changes, ataxia, slurred speech.

  • Concerns while intoxicated: injuries, bleeding (e.g., esophageal varices), legal/vehicular harm.

  • Withdrawal: agitation → seizures; spectrum from mild tremor to life-threatening delirium tremens (DTs).

Hallucinogens (e.g., LSD, psilocybin)

  • Use: perceptual distortions, hallucinations.

  • Concerns: unsafe sex, accidents, loss of reality testing.

  • Withdrawal: headaches, hyperphagia, hypersomnolence, depression (generally less severe physiologically but psychologically distressing).

Opioids (heroin, oxycodone, fentanyl)

  • Use: analgesia, euphoria, miosis, respiratory depression, constipation.

  • Combined with alcohol = synergistic CNS depression → coma/death.

  • Withdrawal: restless legs, myalgias, diarrhea, yawning, piloerection ("cold turkey"), rhinorrhea; rarely fatal but extremely uncomfortable.

Stimulants (cocaine, amphetamines)

  • Use: "rush", tachycardia, hypertension, hypervigilance, hyperglycemia, bronchodilation.

  • Alcohol combo ↑ cardiac toxicity.

  • Withdrawal: profound dysphoria, hypersomnia/insomnia, psychomotor retardation, vivid nightmares.

Sedative-Hypnotics (benzodiazepines, barbiturates)

  • Use: anxiolysis, sedation, slurred speech, hypotension, respiratory depression.

  • Some (flunitrazepam, GHB, ketamine) used as "date-rape" drugs—ethical & forensic implications.

  • Withdrawal: potentially lethal abstinence syndrome with seizures; requires slow taper or substitution therapy.

General Warning Signs of Emerging Substance Use

  • Mood lability, irritability, anhedonia.

  • New peer group; isolation from long-term supports.

  • Weight fluctuation, altered sleep patterns.

  • Neglect of personal health & hygiene.

  • Decline in work/school performance.

  • Unexplained money problems, missing valuables, borrowing.

Alcohol Withdrawal Timeline & Key Manifestations

  • Onset 4–6 h4\text{–}6\,\text{h} post-last drink.

  • Tremor, diaphoresis, tachycardia, hypertension.

  • Nausea/vomiting, anxiety, irritability.

  • Generalized tonic-clonic seizures can occur within 12–48 h12\text{–}48\,\text{h}.

  • DTs: peak 48–72 h48\text{–}72\,\text{h}; hallucinations, autonomic instability, global confusion → up to 5%5\% mortality untreated.

Nursing Role

Prevention

  • Screen for risk factors (family history, trauma, concomitant mental illness).

  • Strengthen protective factors: education, supportive relationships, community programming.

  • Provide anticipatory guidance about substance effects and legal ramifications.

Treatment & Clinical Judgment

  • Manage acute intoxication/withdrawal:
    • Alcohol: benzodiazepines or barbiturates (symptom-triggered dosing), antiepileptics, thiamine to prevent Wernicke–Korsakoff syndrome.

  • Pharmacologic support for abstinence:
    • Naltrexone (opioid receptor antagonist) → ↓ craving & reward.
    • Acamprosate → modulates glutamate for abstinence maintenance.
    • Disulfiram → aversive therapy; acetaldehyde accumulation if alcohol consumed.

  • Non-pharmacologic: motivational interviewing, cognitive-behavioral therapy, peer support, 12-step12\text{-step} programs.

Client & Family Education

  • Treat addiction as a chronic brain disease, not a moral failing.

  • Discuss individual risk factors & triggers; differentiate intoxication vs. withdrawal for each substance.

  • Teach coping skills, relapse-prevention planning, and the importance of milieu safety.

  • Evaluate beliefs & readiness for change using stages-of-change model.

Treatment Settings Continuum

  • Outpatient: weekly counseling + urine drug screens.

  • Intensive Outpatient (IOP): ≥\geq 9 h/week9\,\text{h/week} group & individual therapy.

  • Partial Hospitalization (PHP): day-long programming, home at night.

  • Inpatient: medically managed detox & stabilization.

  • Residential/Rehab: long-term live-in therapeutic community.

Impaired Health-Care Professionals

  • Contributing factors: drug access/diversion, high stress, overtime, low staffing ratios, chronic musculoskeletal pain.

  • Ethical duty to protect patients; mandatory reporting in many jurisdictions.

  • Early intervention programs often offer confidential monitoring & treatment while maintaining public safety.

Disciplinary & Remediation Process (U.S. Model)

  • Complaint (co-worker, employer, self-report) filed with State Board of Nursing (BON).

  • Written response required; BON conducts investigative review.

  • Possible outcomes: dismissal, consent agreement, formal hearing.

  • Nurse Assistance/Alternative-to-Discipline Programs: monitoring, counseling, random drug screens.

  • Non-compliance or severe violation may result in license suspension/revocation; potential criminal charges for diversion.

These notes integrate neurobiological mechanisms, epidemiologic context, clinical manifestations, nursing responsibilities, and legal-ethical considerations to provide a comprehensive framework for understanding and managing substance-related and addiction disorders.